Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

On February 4, 2025, the Delaware Supreme Court, sitting en banc, determined that the Wrongful Acts alleged in a securities class action ...

A securities class action against Alexion Pharmaceuticals Inc. was “related” to an SEC investigation and should have been ...

Alexion has been working hard to flesh out is pipeline as well, snapping up Achillion Pharma, Syntimmune, Wilson Therapeutics and Portola and forging an alliance with gene-silencing specialist ...

Alexion Pharmaceuticals drug Ultomiris is already approved to treat a rare blood disorder, but the company hoped the antibody’s approach could also work in amyotrophic lateral sclerosis.

From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology ...

Pharma is pretty much throwing everything it has at COVID-19 and US rare disease firm Alexion has joined the fray, testing its Ultomiris in a subset of severely ill patients.

Alexion Pharmaceuticals v Amgen (UPC_Coa-405/2024) and Alexion Pharmaceuticals v Samsung Bioepis NL BV (UPC_CoA-402/2024); December 20, 2024.

AstraZeneca recently entered an agreement to acquire Fusion Pharmaceuticals for up to $2.4bn in a strategic move to expand its portfolio. "FDA grants approval for Alexion’s NMOSD treatment" was ...

Bracing for a federal funding drought and higher state costs for Medicare and Medicaid, Gov. Ned Lamont urged pharma ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...